Diabetic CKD — ESENeph MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Add finerenone
KDIGO supports SGLT2i plus maximally tolerated RAAS blockade; in diabetic CKD with albuminuria, adding nonsteroidal MRA (finerenone) reduces progression and CV events. RAAS inhibition should be continued/titrated if tolerated. A loop diuretic is not renoprotective. Additional benefit with finerenone exists.
Reference: KDIGO Guideline (2024): CKD Evaluation and Management